Verge Genomics is taking a novel approach to speed drug discovery for devastating neurodegenerative diseases such as Parkinson's, Alzheimer's and ALS. Rather than spending exhaustive time with animal testing, the San Francisco-based company goes straight to the source. "To succeed in humans, you need to start with humans," says CEO Alice Zhang, whose drug discovery combines artificial intelligence with human genomics. Animal testing can be successful in predicting success for some drugs, but when it comes to neurodegenerative diseases, human brains are far more complex. To keep human patients at the center of the drug discovery process, Zhang's company has built one of the largest databases of brain tissue sequences in the world, with tissue from more than 1,000 human brains.
Apr-29-2021, 12:45:06 GMT